Emerging novel agents for patients with advanced Ewing sarcoma

a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]

Kelly Bailey, Carrye Cost, Ian Davis, Julia Glade-Bender, Patrick Grohar, Peter Houghton, Michael Isakoff, Elizabeth Stewart, Nadia N Laack, Jason Yustein, Damon Reed, Katherine Janeway, Richard Gorlick, Stephen Lessnick, Steven DuBois, Pooja Hingorani

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.

Original languageEnglish (US)
Article number493
JournalF1000Research
Volume8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Peer Review
Ewing's Sarcoma
Oncology
Proxy
Advisory Committees
eribulin
Bone and Bones
Cyclin-Dependent Kinase 6
Cyclin-Dependent Kinase 4
Neoplasms
Bone
Drug Evaluation
Angiogenesis Inhibitors
Protein-Tyrosine Kinases
Tumors
Young Adult
Clinical Trials
Recurrence
Research
Tissue

Keywords

  • Clinical trials
  • Ewing sarcoma
  • Metastasis
  • Relapse
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Emerging novel agents for patients with advanced Ewing sarcoma : a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]. / Bailey, Kelly; Cost, Carrye; Davis, Ian; Glade-Bender, Julia; Grohar, Patrick; Houghton, Peter; Isakoff, Michael; Stewart, Elizabeth; Laack, Nadia N; Yustein, Jason; Reed, Damon; Janeway, Katherine; Gorlick, Richard; Lessnick, Stephen; DuBois, Steven; Hingorani, Pooja.

In: F1000Research, Vol. 8, 493, 01.01.2019.

Research output: Contribution to journalReview article

Bailey, K, Cost, C, Davis, I, Glade-Bender, J, Grohar, P, Houghton, P, Isakoff, M, Stewart, E, Laack, NN, Yustein, J, Reed, D, Janeway, K, Gorlick, R, Lessnick, S, DuBois, S & Hingorani, P 2019, 'Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]', F1000Research, vol. 8, 493. https://doi.org/10.12688/f1000research.18139.1
Bailey, Kelly ; Cost, Carrye ; Davis, Ian ; Glade-Bender, Julia ; Grohar, Patrick ; Houghton, Peter ; Isakoff, Michael ; Stewart, Elizabeth ; Laack, Nadia N ; Yustein, Jason ; Reed, Damon ; Janeway, Katherine ; Gorlick, Richard ; Lessnick, Stephen ; DuBois, Steven ; Hingorani, Pooja. / Emerging novel agents for patients with advanced Ewing sarcoma : a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]. In: F1000Research. 2019 ; Vol. 8.
@article{bc29dd2d797f4006bd884eed473593fb,
title = "Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]",
abstract = "Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.",
keywords = "Clinical trials, Ewing sarcoma, Metastasis, Relapse, Therapy",
author = "Kelly Bailey and Carrye Cost and Ian Davis and Julia Glade-Bender and Patrick Grohar and Peter Houghton and Michael Isakoff and Elizabeth Stewart and Laack, {Nadia N} and Jason Yustein and Damon Reed and Katherine Janeway and Richard Gorlick and Stephen Lessnick and Steven DuBois and Pooja Hingorani",
year = "2019",
month = "1",
day = "1",
doi = "10.12688/f1000research.18139.1",
language = "English (US)",
volume = "8",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Emerging novel agents for patients with advanced Ewing sarcoma

T2 - a report from the Children’s Oncology Group (COG) new agents for ewing sarcoma task force [version 1; peer review: 3 approved]

AU - Bailey, Kelly

AU - Cost, Carrye

AU - Davis, Ian

AU - Glade-Bender, Julia

AU - Grohar, Patrick

AU - Houghton, Peter

AU - Isakoff, Michael

AU - Stewart, Elizabeth

AU - Laack, Nadia N

AU - Yustein, Jason

AU - Reed, Damon

AU - Janeway, Katherine

AU - Gorlick, Richard

AU - Lessnick, Stephen

AU - DuBois, Steven

AU - Hingorani, Pooja

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.

AB - Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated with advanced disease and the need for a clear research strategy, the Children’s Oncology Group Bone Tumor Committee formed the New Agents for Ewing Sarcoma Task Force to bring together experts in the field to evaluate and prioritize new agents for incorporation into clinical trials. This group’s mission was to evaluate scientific and clinical challenges in moving new agents forward and to recommend agents and trial designs to the Bone Tumor Committee. The task force generated a framework for vetting prospective agents that included critical evaluation of each drug by using both clinical and non-clinical parameters. Representative appraisal of agents of highest priority, including eribulin, dinutuximab, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, anti-angiogenic tyrosine kinase inhibitors, and poly-ADP-ribose polymerase (PARP) inhibitors, is described. The task force continues to analyze new compounds by using the paradigm established.

KW - Clinical trials

KW - Ewing sarcoma

KW - Metastasis

KW - Relapse

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85065415318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065415318&partnerID=8YFLogxK

U2 - 10.12688/f1000research.18139.1

DO - 10.12688/f1000research.18139.1

M3 - Review article

VL - 8

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 493

ER -